PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 13, 2026BMC Cancer0 citationsOpen Access

Efficacy of Combined Chemoradiotherapy and Immunotherapy for Advanced Esophageal Cancer

Efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRong LiHHHe-qing HuangLYLi-hua Yang

Discussion

Loading...

Member takes

Overview

Retrospective cohort study evaluates treatment outcomes in patients with localized ESCC, suggesting improved survival with combined therapy.

Key Points

  • This study aims to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with immunotherapy in patients with locally advanced unresectable ESCC.
  • Retrospective cohort design involving 106 patients at Guangxi Medical University from July 2019 to December 2022.
  • Comparison of treatment outcomes between 60 patients receiving CCRT + IT and 46 patients receiving CCRT only.
  • Analysis of objective response rates, progression-free survival, overall survival, and adverse events.
  • CCRT + IT group had a significantly higher objective response rate (76.7% vs. 52.2%; p = 0.008).
  • 1-year progression-free survival was better in the CCRT + IT group (66.7% vs. 41.3%; p = 0.009).
  • 1-year overall survival was also higher in the CCRT + IT group (80.0% vs. 58.7%; p = 0.017).

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/6a0414f679e20c90b4444c7dhttps://doi.org/10.1186/s12885-026-16162-4
View Full Paper
Ask AI
Bookmark
Share